Caliendo G - Search Results

1

A distinct coagulopathy associated with interleukin-2 therapy.

Oleksowicz L, Strack M, Dutcher JP, Sussman I, Caliendo G, Sparano J, Wiernik PH. Oleksowicz L, et al. Among authors: caliendo g. Br J Haematol. 1994 Dec;88(4):892-4. doi: 10.1111/j.1365-2141.1994.tb05135.x. Br J Haematol. 1994. PMID: 7819116

2

A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma.

Koulova L, Novik Y, Caliendo G, Wiernik P, Dutcher J. Koulova L, et al. Among authors: caliendo g. J Immunother. 2005 Nov-Dec;28(6):576-81. doi: 10.1097/01.cji.0000177998.57713.c9. J Immunother. 2005. PMID: 16224275 Clinical Trial.

3

Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha.

Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R, Ciobanu N, et al. Sparano JA, et al. Among authors: caliendo g. Cancer. 1991 Oct 1;68(7):1538-44. doi: 10.1002/1097-0142(19911001)68:7<1538::aid-cncr2820680714>3.0.co;2-2. Cancer. 1991. PMID: 1893354

4

Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission.

Wiernik PH, Dutcher JP, Todd M, Caliendo G, Benson L. Wiernik PH, et al. Among authors: caliendo g. Am J Hematol. 1994 Sep;47(1):41-4. doi: 10.1002/ajh.2830470109. Am J Hematol. 1994. PMID: 8042615 Clinical Trial.

5

Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2.

Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G, et al. Walpole ET, et al. Among authors: caliendo g. J Immunother Emphasis Tumor Immunol. 1993 May 4;13(4):275-81. doi: 10.1097/00002371-199305000-00007. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8101452 Clinical Trial.

6

Phase II trial of merbarone in patients with malignant brain tumors.

Malik UR, Dutcher JP, Caliendo G, Lasala P, Mitnick R, Wiernik PH. Malik UR, et al. Among authors: caliendo g. Med Oncol. 1997 Sep-Dec;14(3-4):159-62. doi: 10.1007/BF02989644. Med Oncol. 1997. PMID: 9468039 Clinical Trial.

7

Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma.

Wu J, Caliendo G, Hu XP, Dutcher JP. Wu J, et al. Among authors: caliendo g. Med Oncol. 1998 Apr;15(1):44-9. doi: 10.1007/BF02787344. Med Oncol. 1998. PMID: 9643530

8

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins M. Dutcher JP, et al. Among authors: caliendo g. Cancer J Sci Am. 1997 May-Jun;3(3):157-62. Cancer J Sci Am. 1997. PMID: 9161781 Clinical Trial.

9

Nursing guidelines and discharge planning for patients receiving recombinant interleukin-2.

Caliendo G, Joyce D, Altmiller MC. Caliendo G, et al. Semin Oncol Nurs. 1993 Aug;9(3 Suppl 1):25-31. Semin Oncol Nurs. 1993. PMID: 8210791 No abstract available.

10

Arylpiperazine Derivatives and Cancer: A New Challenge in Medicinal Chemistry.

Andreozzi G, Corvino A, Severino B, Magli E, Perissutti E, Frecentese F, Santagada V, Caliendo G, Fiorino F. Andreozzi G, et al. Among authors: caliendo g. Pharmaceuticals (Basel). 2024 Oct 2;17(10):1320. doi: 10.3390/ph17101320. Pharmaceuticals (Basel). 2024. PMID: 39458961 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters